SS Innovations International, Inc. (NASDAQ: SSII) has reported significant growth in the adoption and utilization of its SSi Mantra surgical robotic system, according to a recent update. As of September 8, 2026, the system has been used in 14,103 cumulative procedures, a 79% increase from 7,885 procedures at the end of 2025. The installed base of SSi Mantra systems has also risen 42%, from 168 to 238 units worldwide.
The company’s expansion now spans 12 countries, with approximately 1,500 physicians trained on the platform. The SSi Mantra has been employed in more than 170 types of surgical procedures, underscoring its versatility. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines.
SS Innovations also highlighted 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of August 31, 2026. Among these was a telesurgery performed over a distance of more than 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, demonstrating the system’s efficiency and reliability in high-volume settings.
Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. Additionally, SS Innovations believes European Union CE marking certification can be obtained by year-end 2026. These regulatory clearances would open major new markets for the company, potentially accelerating adoption in the U.S. and Europe.
The growth of SS Innovations matters because it reflects a broader trend toward making robotic surgery more affordable and accessible. The company’s vision is to democratize robotic surgery, particularly in emerging markets where advanced surgical technologies have historically been limited. An American company headquartered in India, SS Innovations develops the SSi Mantra system and the SSi Mudra suite of surgical instruments, which support a variety of procedures including cardiac surgery. The company’s cost-effective and user-friendly solutions are designed to reach a larger segment of the global population.
For investors and the medical community, the reported numbers signal strong momentum. The 79% increase in procedures and 42% growth in installed base indicate rising trust in the platform. The training of 1,500 physicians and the performance of complex telesurgeries further validate the system’s capabilities. If regulatory approvals are secured as anticipated, SS Innovations could significantly expand its footprint in the world’s largest healthcare markets, intensifying competition in the surgical robotics industry and potentially lowering costs for hospitals and patients.
To view the full report, visit https://ibn.fm/DJILj. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII.
